The FDA approved Viridian Therapeutics’ thyroid eye disease drug veligrotug for the condition’s treatment, launching a new competitive chapter alongside Amgen’s Tepezza. Viridian said the product will be marketed as Lumvoa and is expected to be priced “in line with” Tepezza. The decision increases pressure on Tepezza’s franchise by adding a second targeted option in thyroid eye disease. For biotech and specialty pharma, the approval also highlights ongoing differentiation strategies in orbit-inflammation indications where efficacy and safety profiles are central to payer and clinician uptake. With competition likely to intensify after label details land, manufacturers and partners will watch real-world adoption and formulary decisions closely.